BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT), a clinical-stage biotechnology company focused on novel immunotherapies for cancer care, has announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, TX.
The presentation is scheduled for Friday, November 8, 2024, from 9:00 am to 7:00 pm CST at the George R. Brown Convention Center. BriaCell's Chief Scientific Officer, Dr. Miguel Lopez-Lago, expressed excitement about presenting their data at this prestigious conference. The company aims to continue investigating novel targeted immunotherapy candidates for breast and prostate cancer patients. After the presentation, the poster will be available on BriaCell's website.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT), un'azienda biotecnologica in fase clinica focalizzata su nuove immunoterapie per la cura del cancro, ha annunciato una presentazione di poster alla 39ª Riunione Annuale della Società per l'Immunoterapia del Cancro (SITC). L'evento si svolgerà dal 6 al 10 novembre 2024, a Houston, TX.
La presentazione è programmata per venerdì 8 novembre 2024, dalle 9:00 alle 19:00 CST presso il George R. Brown Convention Center. Il Direttore Scientifico di BriaCell, Dr. Miguel Lopez-Lago, ha espresso entusiasmo per la presentazione dei loro dati a questa prestigiosa conferenza. L'azienda mira a continuare a indagare nuovi candidati per immunoterapie mirate per pazienti affetti da cancro al seno e alla prostata. Dopo la presentazione, il poster sarà disponibile sul sito web di BriaCell.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT), una empresa biotecnológica en etapa clínica centrada en nuevas inmunoterapias para el tratamiento del cáncer, ha anunciado una presentación de póster en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC). El evento se llevará a cabo del 6 al 10 de noviembre de 2024, en Houston, TX.
La presentación está programada para el viernes 8 de noviembre de 2024, de 9:00 a.m. a 7:00 p.m. CST en el Centro de Convenciones George R. Brown. El Director Científico de BriaCell, Dr. Miguel Lopez-Lago, expresó su entusiasmo por presentar sus datos en esta prestigiosa conferencia. La empresa busca seguir investigando nuevos candidatos a inmunoterapia dirigida para pacientes con cáncer de mama y próstata. Después de la presentación, el póster estará disponible en el sitio web de BriaCell.
브리아셀 테라퓨틱스 주식회사(Nasdaq: BCTX, BCTXW; TSX: BCT)는 암 치료를 위한 새로운 면역 요법에 중점을 둔 임상 단계의 생명공학 회사로, 암 면역 요법 학회(SITC) 제39회 연례 회의에서 포스터 발표를 발표했습니다. 이 행사는 2024년 11월 6일부터 10일까지 텍사스주 휴스턴에서 열릴 예정입니다.
발표는 2024년 11월 8일 금요일 오전 9시부터 오후 7시까지 CST 시간에 조지 R. 브라운 컨벤션 센터에서 진행됩니다. 브리아셀의 수석 과학 책임자인 미겔 로페스라고 박사는 이 저명한 회의에서 그들의 데이터를 발표하게 되어 기쁘다고 밝혔습니다. 이 회사는 유방암 및 전립선암 환자를 위한 새로운 표적 면역 요법 후보를 계속 조사하는 것을 목표로 하고 있습니다. 발표 후, 포스터는 브리아셀의 웹사이트에서 확인할 수 있습니다.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT), une entreprise de biotechnologie en phase clinique se concentrant sur de nouvelles immunothérapies pour le traitement du cancer, a annoncé une présentation de poster lors de la 39e Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (SITC). L'événement aura lieu du 6 au 10 novembre 2024, à Houston, TX.
La présentation est prévue pour le vendredi 8 novembre 2024, de 9h00 à 19h00 CST au George R. Brown Convention Center. Le Directeur Scientifique de BriaCell, Dr. Miguel Lopez-Lago, a exprimé son enthousiasme à l'idée de présenter leurs données lors de cette conférence prestigieuse. L'entreprise vise à continuer à explorer de nouveaux candidats en immunothérapie ciblée pour les patients atteints de cancer du sein et de la prostate. Après la présentation, le poster sera disponible sur le site Web de BriaCell.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neuartige Immuntherapien zur Krebsbehandlung konzentriert, hat eine Posterpräsentation auf der 39. Jahresversammlung der Gesellschaft für Immuntherapie gegen Krebs (SITC) angekündigt. Die Veranstaltung findet vom 6. bis 10. November 2024 in Houston, TX, statt.
Die Präsentation ist für Freitag, den 8. November 2024, von 9:00 bis 19:00 Uhr CST im George R. Brown Convention Center vorgesehen. Der Chief Scientific Officer von BriaCell, Dr. Miguel Lopez-Lago, äußerte seine Vorfreude darauf, ihre Daten auf dieser renommierten Konferenz präsentieren zu dürfen. Das Unternehmen strebt an, weiterhin neuartige zielgerichtete Immuntherapiekandidaten für Brust- und Prostatakrebspatienten zu untersuchen. Nach der Präsentation wird das Poster auf der Website von BriaCell verfügbar sein.
- Presentation at a prestigious cancer immunotherapy conference
- Ongoing research in novel targeted immunotherapies for breast and prostate cancer
- None.
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.
“We are thrilled to be invited to present our data at this prestigious conference,” stated Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “We look forward to continuing our investigations of novel targeted immunotherapy candidates in clinical studies with the goal of making a positive contribution to the lives of breast cancer and prostate cancer patients.”
The details about the presentation and session Information are as follows:
Location: Exhibit Halls A B George R. Brown Convention Center, Houston, TX
Date and Time: Friday, Nov. 8, 2024, 9:00 am -7:00 pm CST
Following the presentation, a copy of the poster will be posted on https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell continuing its clinical study investigations of its novel targeted immunotherapy candidates, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
When and where is BriaCell (BCTX) presenting at the SITC Annual Meeting in 2024?
What types of cancer is BriaCell (BCTX) focusing on with their immunotherapy research?
Where can investors find BriaCell's (BCTX) poster presentation after the SITC conference?
